A Phase II, Double Blind, Exploratory, Parallel-group, Placebo-controlled Clinical Study to Assess Two Dosing Regimens of GSK2402968 for Efficacy, Safety, Tolerability and Pharmacokinetics in Ambulant Subjects With Duchenne Muscular Dystrophy

Trial Profile

A Phase II, Double Blind, Exploratory, Parallel-group, Placebo-controlled Clinical Study to Assess Two Dosing Regimens of GSK2402968 for Efficacy, Safety, Tolerability and Pharmacokinetics in Ambulant Subjects With Duchenne Muscular Dystrophy

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Jul 2016

At a glance

  • Drugs Drisapersen (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Therapeutic Use
  • Acronyms DEMAND II
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 20 Nov 2015 Results of pooled analysis of patients with comparable key baseline characteristics from this and two other clinical trials (700242352 and 700242354) published in a BioMarin Pharmaceutical media release.
    • 23 Apr 2015 According to BioMarin media release, data presented at the American Academy of Neurology (AAN) Annual Meeting.
    • 21 Apr 2015 Results of a pooled analysis of trials DMD114117 and DMD114876 were presented at the 67th Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top